Global Liquid Biopsy Market Report 2019 - World Market to Exhibit a CAGR of 23.31% During 2018-2024 - ResearchAndMarkets.com

The "Global Liquid Biopsy Market - Forecasts from 2019 to 2024" report has been added to ResearchAndMarkets.com's offering.

The global liquid biopsy market is expected to reach $4,380.534 million by 2024 from $1,246.248 million in 2018 growing at a CAGR of 23.31%.

The growth in the market may be attributed to the rising patient population base owing to the rising prevalence of cancer. Rising preference for the non-invasive procedures will also augment the growth of the liquid biopsy market during the given forecast period. However unclear regulatory scenario pertaining to liquid biopsy along with unfavourable reimbursement policies might restrain the growth of the market during the given time frame.

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market.

The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical region. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Major industry players profiled as part of the report are F. Hoffmann-La Roche Ltd , Bio-Rad Laboratories, Inc., Genomic Health.

Key Topics Covered

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Currency

1.5. Assumptions

1.6. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Design

2.2. Secondary Sources

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

4.1. Market Segmentation

4.2. Market Drivers

4.3. Market Restraints

4.4. Market Opportunities

4.5. Porter's Five Force Analysis

4.5.1. Bargaining Power of Suppliers

4.5.2. Bargaining Power of Buyers

4.5.3. Threat of New Entrants

4.5.4. Threat of Substitutes

4.5.5. Competitive Rivalry in the Industry

4.6. Life Cycle Analysis - Regional Snapshot

4.7. Market Attractiveness

5. GLOBAL LIQUID BIOPSY MARKET BY SAMPLE TISSUE

5.1. Blood

5.2. Urine

5.3. Saliva

5.4. Others

6. GLOBAL LIQUID BIOPSY MARKET BY BIOMARKERS

6.1. Circulating Tumor Cells

6.2. Circulating Tumor DNA (CTDNA)

6.3. Neurology E'xtracellular Vesicles (Evs)

6.4. Others

7. GLOBAL LIQUID BIOPSY MARKET BY APPLICATION

7.1. Screening and Diagnostics

7.2. Disease Prognosis

7.3. Drug Response and Resistance

8. GLOBAL LIQUID BIOPSY MARKET BY GEOGRAPHY

8.1. North America

8.1.1. United States

8.1.2. Canada

8.1.3. Mexico

8.2. South America

8.2.1. Brazil

8.2.2. Argentina

8.2.3. Others

8.3. Europe

8.3.1. United Kingdom

8.3.2. Germany

8.3.3. France

8.3.4. Others

8.4. Middle East and Africa

8.4.1. Saudi Arabia

8.4.2. UAE

8.4.3. Israel

8.4.4. Others

8.5. Asia Pacific

8.5.1. China

8.5.2. India

8.5.3. Australia

8.5.4. South Korea

8.5.5. Others

9. COMPETITIVE INTELLIGENCE

9.1. Company Benchmarking and Analysis

9.2. Recent Investment and Deals

9.3. Strategies of Key Players

10. COMPANY PROFILES

10.1. F. Hoffmann-La Roche Ltd.

10.2. Bio-Rad Laboratories, Inc.

10.3. Genomic Health

10.4. QIAGEN

10.5. NeoGenomics Laboratories, Inc.

10.6. OncoCyte Corporation

10.7. Biocept, Inc.

10.8. LungLife AI, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/djk684

View source version on businesswire.com: https://www.businesswire.com/news/home/20191223005533/en/